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InterferonAfrican swine fever virus (ASFV) encodes multiple copies of MGF360 and MGF530/505 gene families.
These genes have been implicated in the modulation of the type I interferon (IFN) response. We investi-
gated the effect of modulating the IFN response on virus attenuation and induction of protective immu-
nity by deleting genes MGF360 (MGF360-10L, 11L, 12L, 13L, 14L) and MGF530/505 (MGF530/505-1R, 2R
and 3R) and interrupting genes (MGF360-9L and MGF530/505-4R) in the genome of the virulent ASFV
isolate Benin 97/1. Replication of this deletion mutant, BeninDMGF, in porcine macrophages in vitro
was similar to that of the parental virulent virus Benin 97/1 and the natural attenuated isolate
OURT88/3, which has a similar deletion of MGF360 and 530/505 genes. Levels of IFN-b mRNA in macro-
phages infected with virulent Benin 97/1 isolate were barely detectable but high levels were detected in
macrophages infected with OURT88/3 and intermediate levels in macrophages infected with
BeninDMGF. The data confirms that these MGF360 and MGF530/505 genes have roles in suppressing
induction of type I IFN. Immunisation and boost of pigs with BeninDMGF showed that the virus was
attenuated and all pigs (5/5) were protected against challenge with a lethal dose of virulent Benin
97/1. A short transient fever was observed at day 5 or 6 post-immunisation but no other clinical signs.
Following immunisation and boost with the OURT88/3 isolate 3 of 4 pigs were protected against chal-
lenge. Differences were observed in the cellular and antibody responses in pigs immunised with
BeninDMGF compared to OURT88/3. Deletion of IFN modulators is a promising route for construction
of rationally attenuated ASFV candidate vaccine strains.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
African swine fever (ASF) is an acute haemorrhagic disease of
domestic pigs that can have a devastating socio-economic impact
in affected regions. Currently these include sub-Saharan Africa,
Trans-Caucasus, Russian Federation, parts of E. Europe and Sardinia
[1]. No vaccine is available limiting options for control [2,3]. ASF is
caused by a large, cytoplasmic, double-stranded DNA virus, African
swine fever virus (ASFV) [4] with a genome varying between 170
and 193 kbp, mainly due to variation in the copy numbers of differ-
ent multigene families (MGFs) [5].
Immunisation of pigs with an attenuated ASFV, OURT88/3, can
protect against lethal challenge with isolates from the same geno-
type I and other genotypes [6,7] and the protection is dependent onCD8+ cells [8]. This isolate has been used as a model to understand
the correlates for induction of protection and was therefore
included in this study for comparison. The OURT88/3 strain has a
large contiguous deletion of genes MGF360-10L, 11L, 12L, 13L,
14L, MGF530/505-1R, 2R and truncation of gene MGF530/505-3R
[9]. Deletion of similar MGF genes from the Pr4 genotype XX strain
increased induction of type I interferon (IFN) and interferon stim-
ulated genes in macrophages infected in vitro. It was suggested
that this inability to control the IFN response was responsible for
the attenuation of the deletion mutant in pigs [10]. In addition,
deletion of these genes from a genotype II Georgia strain reduced
virulence in pigs and induced protection against challenge [11].
In this study we investigated the impact of deleting or interrupting
additional copies of MGF360 and 530/505 genes compared to those
studied previously from a virulent genotype I isolate, Benin 97/1.
MGF360-10L, 11L, 12L, 13L, 14L and MGF530/505-1R, 2R and 3R
were deleted and MGF360-9L and MGF530/505-4R inactivated.
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ated OURT88/3 strain, a well characterised model for induction of
protection, by in vitro infections and immunisation and challenge
in pigs. The results highlight differences between interferon induc-
tion and in vivo host responses.2. Materials and methods
2.1. Viruses and cells
The Benin 97/1 and OURT88/3 isolates were described previ-
ously [6,7,9]. Viruses were cultured in porcine bone marrow
(PBMs) or alveolar macrophages (PAMs). Virus titres were deter-
mined by haemadsorbtion (HAD50/ml) [12] or by immunofluores-
cence using antibodies against ASFV early protein p30 [13].
2.2. Construction of ASFV BeninDMGF virus
Right and left genome fragments flanking genes MGF360-10L,
11L, 12L, 13L, 14L and MGF530/505-1R, 2R and 3R (Fig. 1) were
amplified by PCR and cloned into the vector pMGFloxPGUS vector
[14] to construct plasmid pDMGFGUS. PBMs were infected withFig. 1. ASFV genome showing position of deletions in BeninDMGF genome. Panel A sh
position 16 and 32 kbp. Open reading frames are indicated with arrows and labelled abov
shown as a dashed line. The ORFs MGF360-9L and MGF530/505-4R which are interrup
sequence of the Benin 97/1 isolate at the N-terminus of the MGF360-9L and MGF 530/50
indicating the sequences deleted from the start of these ORFs.Benin 97/1 isolate at a multiplicity of infection (MOI) of 3–5 and
transfected with plasmid pDMGFGUS using TRANS-IT LT-1 (Mirus
Bio Madison USA). Recombinant viruses expressing the b-GUS gene
were identified by incubation of infected cells in the presence of
5-bromo-4-chloro-1H-indol-3-yl b-D-glucopyranosiduronic acid
and purified by limiting dilution [13]. The purity of the recombi-
nant virus, BeninDMGF, was tested by PCR assays (Supplementary
Fig. 1). Sequencing of a fragment amplified from across the site of
the deletion confirmed the position of the deletion and removal of
the first 5 nucleotides of the MGF360-9L gene and the first 7
nucleotides of the MGF530/505-4R genes including the ATG trans-
lation start codons and respective promoters (Fig. 1).
Two independently constructed deletion mutants were isolated
and confirmed to have the same phenotypes (data not shown).2.3. Analysis of IFN-b transcript levels
PAMs (5  105 cells) were infected with ASFV or mock-infected.
At selected times, RNA was extracted (RNeasy mini kit, Qiagen,
Hilden Germany) with on column DNase I digestion. cDNA was
generated using the Superscript III reverse transcriptase kit (Invit-
rogen, Waltham. MA USA). IFN-b transcripts were measured byows a diagram of the left end of the genome of ASFV Benin 97/1 isolate between
e or below. Below the position of deletions in BeninDMGF and OURT88/3 strains are
ted in the BeninDMGF isolate are outlined with dashed lines. Panel B shows the
5-4R genes in the upper panel and below the same region of the BeninDMGF strain
Fig. 2. Replication kinetics of Benin 97/1, BeninDMGF and OURT88/3 viruses. Pig
bone marrow macrophages were infected at a low multiplicity of infection (0.3)
with Benin 97/1, BeninDMGF and OURT88/3 isolates as indicated. At various hours
post-infection up to 96 h total virus from cells and supernatants was harvested and
titrated. Results show means and standard error of the mean (SEM) from two
biological replicates using cells from different pigs each of which was assayed in
duplicate.
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ter Mix (Life Technologies, UK). A DNA blocking oligonucleotide
with a ddC modification at the 30 end was used to avoid amplifica-
tion of genomic DNA: CCT TCC AGT ATA AAT AGC CTA TGG AGA
AAG AAC ATT CAC ACT GCA CA-ddC. The forward primer 50 termi-
nus overlapped the 30 terminus of the blocking oligonucleotide
(ATT CAC ACT GCA CAC TCC TGA A) and the reverse primer
sequence was: GCA CAT CAT AGC TCA TGG AA. PCR amplification
included 10 min at 95⁰C, 40 cycles of 30 s at 95 C, 15 s at 70 C
and 1 min at 65 C. GAPDH expression was used as internal control,
using the primers: TCA ACG ACC ACT TTG TCA AGC and GGT GGT
CCA GGG GCT CTT A. IFN-b and GAPDH copy numbers were calcu-
lated by the standard curve method and results are presented as
the IFN-b/GAPDH ratio. Assays were carried out in duplicate. Tran-
scripts from the ASFV B646L gene were measured by qRTPCR [15].
2.4. Immunisation and challenge of pigs
Experiments under Home Office licence PPL 70-6369 were car-
ried out in SAPO4 high containment at The Pirbright Institute using
Large White X Landrace pigs (15–20 kg). Clinical signs were mon-
itored daily [7]. Blood samples were collected on different days and
tissues (spleen, tonsil, gastro-hepatic, sub-mandibular and mesen-
teric lymph nodes) were collected at termination.
2.5. Quantitative PCR analysis of virus genome copy numbers
DNA was extracted from whole peripheral blood and from tis-
sue samples. Virus genome copy numbers were determined by
qPCR [15].
2.6. Assay of T cell responses
T cell populations were identified in blood samples using mouse
anti-porcine CD4 (clone 74.12.4), CD8 (clone 11.295.33) and
gamma delta TCR (clone PPT27) antibodies. Antibodies were incu-
bated with whole blood for 20 min at room temperature and then
red blood cells were lysed (FACS lysing solution, BD Biosciences,
UK). Cells were pelleted by centrifugation and fixed
(4% paraformaldehyde for 30 min). After two washes cells were
analysed by flow cytometry (MACSQuant, Miltenyi Biotec. UK).
Lymphocyte subsets were gated based on cell surface marker stain-
ing using FCS express software (De Novo Software). ASFV specific T
cell responses were measured using an IFN-c ELISPOT assay [7,16].
Peripheral blood mononuclear cells (PBMC) were stimulated with
ASFV or 5 lg/ml phytohaemaglutanin as control.
2.7. Measurement of antibody responses against ASFV
Levels of ASFV specific antibodies in serum were measured
using a competition ASF ELISA kit (INGENASA PPA3 COMPPAC).
2.8. Measurement of cytokine levels in serum
Levels of IL-1b, IL-4, TNFa, IFN-c and IL-10 in serum were mea-
sured using commercially available ELISA kits (R&D Systems,
Abingdon, UK).
2.9. Statistical analysis
Statistical analysis of temperatures, clinical scores and antibody
responses was performed using GraphPad Prism6 software. Signif-
icant differences between groups were determined using two-way
ANOVA followed by Sidak’s multiple comparison test.3. Results
3.1. BeninDMGF deletion mutant virus replicates with similar kinetics
to parental Benin 97/1 and OURT88/3 strains
The contiguous genes MGF360-10L, 11L, 12L, 13L, 14L and
MGF530/505-1R, 2R and 3R were deleted and MGF 360-9L and
MGF 530/505- 4R interrupted in the genome of the Benin 97/1 vir-
ulent isolate (Fig. 1).
PAMs were infected at a low MOI (0.3) with BeninDMGF, Benin
97/1 or OURT88/3 strains and total virus harvested at different
times was titrated. The results, using macrophages from 2 different
pigs, showed similar kinetics of replication reaching a plateau at
48 h post-infection of 1  106 for Benin 97/1 and BeninDMGF
and 1  107 for OURT88/3 (Fig. 2). Thus deletion of these
MGF360 and MGF530/505 genes from the Benin 97/1 genome
did not significantly alter the virus replication kinetics in
macrophages.3.2. Levels of IFN-b mRNA in porcine macrophages are increased
following infection with OURT88/3 and BeninDMGF
PAMs were infected at a MOI of 1 with Benin 97/1, BeninDMGF,
OURT88/3 virus strains or were mock-infected. Levels of mRNA for
porcine IFN-b and the ASFV B646L late gene were determined by
qRTPCR at different times post-infection. Fig. 3 shows typical
results from one of 3 biological replicates using macrophages from
different outbred pigs. Levels of mRNA for the VP72 B646L gene
were similar in infections with the different viruses confirming
that similar levels of infection were obtained. These reached a pla-
teau of 105–106 copy numbers by 10–12 h post-infection (Fig. 3B).
IFN-b mRNA was detected at very low levels or was not
detected in mock-infected cells and in cells infected with Benin
97/1 (Fig. 3A). In contrast high levels of IFN-bmRNA were detected
in macrophages infected with OURT88/3. Intermediate levels were
detected in macrophages infected with BeninDMGF, varying in dif-
ferent biological replicates between 6 and 20% of that detected at
16 h following OURT88/3 infections. Low levels of IFN-b mRNA
were detected from 4 h post-infection reaching a peak by 12 h
which was maintained during the remainder of the time course.
Thus deletion of the members of MGF360 and 530/505 resulted
in an increase in IFN-b gene transcripts, indicating that these genes
have a role in suppressing IFN-b induction.
Fig. 3. Amounts of mRNA for IFN-b and ASFV VP72 (B646L) gene detected at
different times post-infection of macrophages with Benin 97/1, BeninDMGF or
OURT88/3 strains. Porcine alveolar macrophages were infected at a MOI of 1 or
mock-infected. At different times post-infection (x-axis) RNA was extracted and
Panel A shows the amounts of IFN-bmRNA determined by qRTPCR in comparison to
GAPDH (y-axis). Panel B shows copy numbers of VP72 mRNA (B646L gene)
estimated in comparison to control plasmid analysed in parallel. The graph shows
typical results obtained from one of three biological replicates using cells from a
single pig. Each sample was assayed in duplicate.
A.L. Reis et al. / Vaccine 34 (2016) 4698–4705 47013.3. The BeninDMGF deletion mutant virus is attenuated in pigs and
induces a protective response against challenge with parental virus:
Clinical and post-mortem signs
Five pigs were inoculated with the BeninDMGF virus (102
TCID50) and four pigs with the attenuated OURT88/3 isolate (104
TCID50) by the intramuscular (IM) route. After 25 days the pigs
were boosted with the same viruses IM using 104 TCID50. At day
46, the pigs were challenged with the parental Benin 97/1 virus
(104 TCID50 IM) in parallel with three control non-immune pigs.
Four pigs inoculated with BeninDMGF developed a transient fever
of 40–40.5 C for 1 day (21, 22, 23) or 2 days (25) at day 6 or 7 post-
inoculation (Fig. 4). No clinical signs were observed after challenge
with virulent virus.
No clinical signs were observed in pigs post-immunisation with
OURT88/3. Following challenge with virulent Benin 97/1 virus, one
of the pigs (19) developed fever and other clinical signs character-
istic of acute ASF (lethargy, inappetence) at day 3 post-challenge
and was terminated at day 5 post-challenge. Two of the other pigs
(16, 20) in this group had a transient fever of 40–40.5 C at day 4
post-challenge. In summary, pigs immunised with OURT88/3
showed significantly higher temperatures (p = 0.0118) (Fig. 4F)
and clinical scores (Supplementary Fig. 2F) than pigs immunised
with BeninDMGF after challenge. The control group of non-
immune pigs all developed clinical signs typical of acute ASF and
were terminated at day 5 post-challenge. All remaining pigs were
terminated at day 17 post-challenge. Post-mortem examination
of pigs showed lesions typical of acute ASFV in the threenon-immune control pigs (26, 27, 28) and in pig 19. These included
an enlarged haemorrhagic spleen and lymph nodes.3.4. Virus load in blood and tissues
Virus genome (102–106 copies per ml) was detected in blood
from all of the pigs’ post-immunisation with the BeninDMGF virus.
This was detected from day 5 or 7 post-immunisation until days
28–46 and declined over this period to between 104 genome copies
per ml and undetectable levels. Low levels of virus genome (<104
genome copies per ml) were detected in four of the pigs post-
challenge (Fig. 5). None of the pigs immunised with OURT88/3
had detectable levels of virus DNA in blood post-immunisation
(data not shown). Virus genome was detected (106 genome copies
per ml) in blood at day 5 post-challenge from the one pig (19) that
was not protected following challenge. As expected the 3 non-
immune pigs (26, 27, 28) had high levels of ASFV genome in blood
from the onset of clinical signs at day 3 post-challenge (106–107
genome copies per ml) and were terminated at day 5 post-
challenge (Fig. 5D).
Virus genome was detected in the spleen of pig 24 (2.4  103
copies per g tissue) and in the sub-mandibular lymph node of pig
25 (7.8  102 copies per g tissue) but not in the other tissues col-
lected or in samples from other pigs. Virus genome levels typical
for acute ASF (between 106 and 108 genome copies per g of tissue)
were detected in all 5 tissues analysed from the control non-
immune pigs (data not shown).3.5. T cell responses in immunised pigs: IFN-c ELIspot assays
The responses of lymphocytes from immunised pigs were mea-
sured following stimulation of PBMC with live Benin 97/1 isolate or
medium (Fig. 6A and B). High numbers of IFN-c producing cells
were detected following virus stimulation of PBMC isolated before
challenge and at 17 days post-challenge from pigs immunised with
OURT88/3. Responses to medium alone were very low. In contrast
generally low numbers of IFN-c producing cells were induced by
virus stimulation of PBMC from pigs which were immunised with
BeninDMGF. Before challenge only one pig (no 21) showed num-
bers of IFN-c producing cells similar to those observed from pigs
immunised with OURT88/3. These results indicated there may be
a lower specific T cell response to ASFV in pigs immunised with
BeninDMGF compared to OURT88/3. To further investigate we
measured changes in the proportion of different subpopulations
of lymphocytes over the course of the experiment (results shown
as a percentage of the numbers observed at day 0) (Supplementary
Fig. 3). Pigs infected with BeninDMGF showed significantly lower
numbers of circulating CD8+ gamma delta T cells as early as day
20 post-infection. No other major differences between OURT88/3
and BeninDMGF infected animals were observed for the other cell
populations studied.3.6. Antibody responses in immunised pigs
Anti-ASFV VP72 antibodies (Fig. 6C) were first detected from
day 10 post-immunisation and increased until day 38 remaining
at the same level until the experiment was terminated at day 63.
Levels of anti-VP72 antibodies were significantly lower in pigs
immunised with BeninDMGF compared to OURT88/3 on days 10
(p = 0.0006), 17 (p < 0.0001) and 28 (p = 0.0026) post-
immunisation. No virus neutralisation was detected using serum
collected on day 63 from any of the immunised pigs (data not
shown).
Fig. 4. Temperatures after inoculation and challenge of pigs. Panel A and B show temperatures (y-axis) of individual pigs at different days post-inoculation (PI) (x-axis) with
OURT88/3 or BeninDMGF respectively. Panels C and D show temperatures of individual pigs (y-axis) at different days post-challenge (PC) (x-axis) with OURT88/3 or
BeninDMGF respectively. Panel E shows temperatures (y-axis) of control non-immune pigs at different days post-challenge with Benin 97/1 (PC) (x-axis). Panel F shows
means and standard error of the mean (SEM) of temperatures (y-axis) of pigs inoculated with OURT88/3 (teal) or BeninDMGF (purple) at different days post-challenge (x-
axis). Asterisk indicates results significantly different (*P 6 0.05) between groups.
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Comparison of the levels of cytokines in sera from pigs immu-
nised with BeninDMGF and OURT88/3 showed an increase in the
amount of IFN-c detected at days 5 and 7 post-immunisation in
four of the pigs immunised with BeninDMGF (Supplementary
Fig. 4). This increase was not observed in pigs infected with the
OURT88/3 isolate. At other days tested IFN-c levels remained
low, with the exception of the pig that was infected with OURT88/3
and did not survive challenge. In this pig there was a significant
increase in IFN-c three days post-challenge. There were no signif-
icant differences observed in levels of IL-1b, IL-4, TNFa or IL-10 in
pigs infected with BeninDMGF compared to OURT88/3 (data not
shown).4. Discussion
We extended studies on the impact of deleting or interrupting
multiple copies of genes belonging to MGF360 and MGF530/505
on virus replication and type I IFN induction in macrophages in cul-
ture and virus pathogenesis and induction of protection in pigs.The genes deleted or interrupted from the virulent Benin 97/1 iso-
late (MGF360-9L, 10L, 11L, 12L, 13L, 14L MGF530/505 -1R, 2R, 3R,
4R) included one gene (MGF530/505-4R) in addition to those
deleted from the attenuated OURT88/3 isolate [9] and 3 in addition
to those from Pr4 and Georgia [10,11]. Our results indicate that
these genes are involved in suppressing type I IFN induction in
infected macrophages in culture since IFN-b mRNA was consis-
tently observed in macrophages infected with the deletion mutant
but not those infected with the virulent parental virus Benin 97/1.
Higher levels of IFN-b mRNA were consistently induced in macro-
phages infected with OURT88/3 compared to BeninDMGF suggest-
ing that other genes altered in the OURT88/3 isolate have a similar
role. These may include MGF360-5L and MGF530/505-5R, since
these are present in Benin 97/1 and BeninDMGF but not in
OURT88/3 [9]. The mechanism by which the MGF360 and
MGF530/505 genes act is unknown. The relatively high sequence
divergence between different gene copies suggests they could have
different molecular targets.
The numbers of MGF360 and 530/505 genes encoded by differ-
ent isolates vary and thus the same gene deletions may vary in
effect dependent on the isolate. Our results confirm that the dele-
tion of this subset of MGF360 and 530/505 genes from a virulent
Fig. 5. Virus genome copies detected in blood and tissues. Blood samples were collected at different days post-inoculation (PI) or post-challenge (PC) with Benin 97/1 (x-axis)
and amounts of virus DNA present determined by qPCR in comparison with a control plasmid (y-axis). Panel A shows virus genome copies per ml in blood from individual pigs
post-inoculation with BeninDMGF. No virus DNA was detected in blood from pigs post-inoculation with OURT/88/3 strain. Panels B, C, D show virus genome copies per ml of
blood detected in individual pigs inoculated with OURT88/3 (Panel B), BeninDMGF (Panel C) and non-immune pigs (Panel D) post-challenge with Benin 97/1. Results shown
are averages of duplicate samples.
A.L. Reis et al. / Vaccine 34 (2016) 4698–4705 4703genotype I isolate results in virus attenuation and induction of pro-
tection. Thus this deletion may be used to rationally attenuate vir-
ulent isolates from any ASFV genotype. We demonstrated a
correlation between increased induction of type I IFN-b mRNA in
macrophages infected in vitro and virus attenuation in pigs. Repli-
cation of virulent isolates in macrophages is resistant to pre-
treatment with high levels of IFN-a whereas OURT88/3 isolate
was slightly sensitive (102 reduction in titre) [17]. Thus the
induced type I IFN may contribute to control replication of
OURT88/3 and BeninDMGF by inducing an antiviral response and
by activating innate immunity and thus reduce virus pathogenesis
in pigs. The higher levels of virus genome detected in blood follow-
ing immunisation of pigs with BeninDMGF compared to OURT88/3
may result from the intact EP402R gene in BeninDMGF. This gene
encodes the CD2v protein which is required for binding of virus
particles and infected cells to red blood cells. This is predicted to
result in binding of extracellular virions to red blood cells and thus
increase levels of virus detected in blood. This may also result in
increased dissemination of virus in pigs [18,19]. Although we did
not detect virus genome in blood post-immunisation with
OURT88/3 transient viremia may have been missed in intervals
between sampling. Other genome differences have been described
between OURT88/3 and Benin 97/1 [9] and may also contribute to
differences between the clinical signs and protection induced by
the two viruses.In an attempt to identify correlates of protection the immune
responses were compared between pigs immunised with
BeninDMGF and OURT88/3, a well-characterised model for induc-
tion of protection. As previously observed [7], immunisation with
OURT88/3 results in the induction of high numbers of IFN-c pro-
ducing lymphocytes following stimulation with ASFV. Interest-
ingly, pig 19 although showing similar responses to the other
pigs inoculated with OURT88/3 did not survive challenge. The
lower numbers of IFN-c producing lymphocytes observed follow-
ing stimulation of lymphocytes from the pigs immunised with
BeninDMGF were not explained by a general depletion in numbers
of lymphocytes. No significant differences in the proportions of
total CD4+, CD8+, CD4+CD8+ and total gamma delta T cells were
observed between the OURT88/3 and BeninDMGF immunised pigs.
Alternatively, the prolonged viremia observed in pigs immunised
with BeninDMGF could be associated with the decreased IFN-c T
cell responses. However results obtained in our laboratory using
another deletion mutant in the same Benin 97/1 background,
showed high numbers of IFN-c producing cells in pigs with similar
high viremias (Reis et al., unpublished data). Taken together, these
results suggest that in addition to IFN-c production, protection
may be correlated with induction of a different T cell response.
Pigs immunised with BeninDMGF showed an increase in serum
IFN-c at days 5 and 7 post infection. This cytokine was most prob-
ably secreted by NK or NKT cells, since it was too early for the devel-
Fig. 6. Immune responses in vaccinated pigs. Panels A and B show numbers of IFN-c producing cells by ELISPOT assays using PBMC stimulated with ASFV Benin 97/1. PBMC
isolated on day 46 post-inoculation (panel A) or day 17 post-challenge (panel B) with OURT88/3 or BeninDMGF were stimulated ex vivo with either medium alone or Benin
97/1 virus. Results show mean and SD of numbers of IFN-c producing cells per 106 lymphocytes (y-axis) and type of stimulation (x-axis) for the different pigs. Panel C shows
the antibody response to ASFV post-immunisation and challenge. Sera were collected at different days post-inoculation (x-axis) of pigs with OURT88/3 or BeninDMGF strains.
Levels of anti-VP72 antibodies were detected using a blocking ELISA assay. The percentage of blocking is shown (y-axis). Results show mean and SEM for the different groups
of pigs and asterisks indicate days on which statistically significant differences were observed between the groups of pigs (**P 6 0.01; ***P 6 0.001; ****P 6 0.0001).
4704 A.L. Reis et al. / Vaccine 34 (2016) 4698–4705opment of specific T lymphocytes. IFN-c plays an import role in the
establishment of the adaptive immunity, for example by enhancing
MHC class II presentation and favouring a Th1 type response, and
therefore may have had a positive impact in protection.
Our results indicate that deletion of IFN modulators is a promis-
ing route for rational attenuation of virulent ASFV to produce can-
didate vaccine strains.
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